Compare RVSB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | RNTX |
|---|---|---|
| Founded | 1923 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 89.0M |
| IPO Year | 1997 | N/A |
| Metric | RVSB | RNTX |
|---|---|---|
| Price | $5.27 | $0.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $10.00 |
| AVG Volume (30 Days) | 204.6K | ★ 579.2K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $0.85 |
| 52 Week High | $6.22 | $2.18 |
| Indicator | RVSB | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 37.92 |
| Support Level | $5.24 | $0.85 |
| Resistance Level | $5.37 | $1.05 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 22.99 | 0.05 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.